6.
Syed Y
. Tagraxofusp: First Global Approval. Drugs. 2019; 79(5):579-583.
DOI: 10.1007/s40265-019-01087-z.
View
7.
Mazor R, Vassall A, Eberle J, Beers R, Weldon J, Venzon D
. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci U S A. 2012; 109(51):E3597-603.
PMC: 3529021.
DOI: 10.1073/pnas.1218138109.
View
8.
Zhou K, Liu S, Hardenbrook N, Cui Y, Krantz B, Zhou Z
. Atomic Structures of Anthrax Prechannel Bound with Full-Length Lethal and Edema Factors. Structure. 2020; 28(8):879-887.e3.
PMC: 7519843.
DOI: 10.1016/j.str.2020.05.009.
View
9.
Arora N, Leppla S
. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem. 1993; 268(5):3334-41.
View
10.
Allured V, Collier R, Carroll S, McKay D
. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A. 1986; 83(5):1320-4.
PMC: 323067.
DOI: 10.1073/pnas.83.5.1320.
View
11.
Mazor R, King E, Pastan I
. Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. Am J Pathol. 2018; 188(8):1736-1743.
PMC: 6099333.
DOI: 10.1016/j.ajpath.2018.04.016.
View
12.
Dong M, Yeh F, Tepp W, Dean C, Johnson E, Janz R
. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312(5773):592-6.
DOI: 10.1126/science.1123654.
View
13.
Mansfield M, Doxey A
. Genomic insights into the evolution and ecology of botulinum neurotoxins. Pathog Dis. 2018; 76(4).
DOI: 10.1093/femspd/fty040.
View
14.
Kreitman R, Wilson W, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald D
. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001; 345(4):241-7.
DOI: 10.1056/NEJM200107263450402.
View
15.
Shafiee F, Aucoin M, Jahanian-Najafabadi A
. Targeted Diphtheria Toxin-Based Therapy: A Review Article. Front Microbiol. 2019; 10:2340.
PMC: 6813239.
DOI: 10.3389/fmicb.2019.02340.
View
16.
Jack S, Madhivanan K, Ramadesikan S, Subramanian S, Edwards 2nd D, Elzey B
. A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. Int J Cancer. 2019; 146(2):449-460.
PMC: 10303116.
DOI: 10.1002/ijc.32719.
View
17.
Senzel L, Gordon M, Blaustein R, Oh K, Collier R, Finkelstein A
. Topography of diphtheria Toxin's T domain in the open channel state. J Gen Physiol. 2000; 115(4):421-34.
PMC: 2233753.
DOI: 10.1085/jgp.115.4.421.
View
18.
Naglich J, Metherall J, Russell D, Eidels L
. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell. 1992; 69(6):1051-61.
DOI: 10.1016/0092-8674(92)90623-k.
View
19.
Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J
. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget. 2016; 7(21):29916-26.
PMC: 5058652.
DOI: 10.18632/oncotarget.9171.
View
20.
Khounlo R, Kim J, Yin L, Shin Y
. Botulinum Toxins A and E Inflict Dynamic Destabilization on t-SNARE to Impair SNARE Assembly and Membrane Fusion. Structure. 2017; 25(11):1679-1686.e5.
PMC: 5685167.
DOI: 10.1016/j.str.2017.09.004.
View